Premium Nahrungsergänzungsmittel | artgerecht

Apoptosis Inhibition – Mechanisms, Causes and Therapy

Apoptosis inhibition refers to the suppression of programmed cell death. It plays a key role in cancer development and is a major target in modern oncological therapies.

Regular tips about health Regular tips about health

Things worth knowing about "Apoptosis Inhibition"

Apoptosis inhibition refers to the suppression of programmed cell death. It plays a key role in cancer development and is a major target in modern oncological therapies.

What Is Apoptosis Inhibition?

Apoptosis inhibition refers to the biological or pharmacological process by which programmed cell death (apoptosis) is suppressed or prevented. Under normal conditions, apoptosis is a vital mechanism that eliminates damaged, redundant, or potentially dangerous cells. When this process is inhibited, cells can survive and proliferate uncontrollably – a hallmark feature of many diseases, especially cancer.

Biological Basis of Apoptosis

Apoptosis is triggered through two main pathways:

Intrinsic pathway: Activated by intracellular stress, such as DNA damage. It is mediated through mitochondria and regulated by proteins of the Bcl-2 family.
Extrinsic pathway: Triggered by external signals, for example via death receptors such as FAS or TNFR1 on the cell surface.

Both pathways converge on the activation of caspases – enzymes that systematically dismantle the cell. Apoptosis-inhibiting mechanisms interfere at various points within these signaling cascades.

Mechanisms of Apoptosis Inhibition

Overexpression of Anti-apoptotic Proteins

Proteins such as Bcl-2, Bcl-xL, and MCL-1 block the release of cytochrome c from mitochondria, thereby preventing the initiation of programmed cell death. These proteins are frequently overexpressed in tumor cells.

Inactivation of Pro-apoptotic Factors

Pro-apoptotic proteins such as BAX, BAK, and BIM are often inactivated by mutations or functionally suppressed in cancer cells, preventing the apoptotic signal from being transmitted.

Inhibitor of Apoptosis Proteins (IAPs)

IAPs (e.g., Survivin, XIAP) are a protein family that directly inhibits caspases, thereby preventing cell breakdown. They are overexpressed in numerous tumors and represent promising therapeutic targets.

Mutation of the Tumor Suppressor Gene p53

The protein p53 is considered the central guardian of the genome. Upon DNA damage, it activates apoptosis. Mutations in the TP53 gene – detectable in more than 50% of all cancers – cause this protective mechanism to fail, allowing severely damaged cells to survive.

Clinical Significance of Apoptosis Inhibition

Dysregulated apoptosis is a fundamental characteristic of malignant diseases. It contributes to:

Uncontrolled tumor growth
Resistance to chemotherapy and radiation therapy
Metastasis of cancer cells
Treatment failure and disease relapse

Apoptosis inhibition may also play a role in autoimmune diseases, chronic inflammation, and neurodegenerative conditions.

Therapeutic Approaches to Overcome Apoptosis Inhibition

The targeted reactivation of apoptosis in tumor cells is a central goal of modern oncology. Key approaches include:

BH3 mimetics: Compounds such as Venetoclax mimic pro-apoptotic BH3 proteins and displace anti-apoptotic proteins like Bcl-2. Venetoclax is clinically approved for certain leukemias and lymphomas.
IAP inhibitors (Smac mimetics): These agents mimic the endogenous protein SMAC/DIABLO and block IAP proteins to restore caspase activity.
p53 reactivation: Compounds such as APR-246 (eprenetapopt) aim to restore mutant p53 to its active form and are under investigation in clinical trials.
Conventional chemotherapeutics: Many classical cytostatic agents (e.g., cisplatin, doxorubicin) act indirectly by inducing DNA damage that is intended to trigger apoptosis via p53.

References

Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-674. DOI: 10.1016/j.cell.2011.02.013
Bhola PD, Letai A. Mitochondria – Judges and Executioners of Cell Death Sentences. Molecular Cell. 2016;61(5):695-704. DOI: 10.1016/j.molcel.2016.02.019
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nature Reviews Drug Discovery. 2017;16(4):273-284. DOI: 10.1038/nrd.2016.253

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.